Vicore Pharma (VCRE)

Develops oral therapies for idiopathic pulmonary fibrosis, or IPF, centered on buloxibutid, an investigational AT2 receptor agonist. Its strategy also includes discovery-stage follow-on AT2 receptor agonists and licensing or partnering where geography, indication, or commercialization scale warrants.

Operates across Sweden, Denmark, the United States, and international trial sites, while outsourcing clinical execution to investigators and CROs and supply to European CMOs. Japan is licensed to Nippon Shinyaku; elsewhere there is no commercial organization or product-sales revenue.

Is substantially dependent on buloxibutid, whose ongoing randomized ASPIRE study must establish safety and efficacy before a later-stage program or approval path is supported. Development and potential commercialization depend on external contractors, regulatory review, and a build-or-partner decision.